Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model

Cancer Research

Volumn 70, Issue 4, 2010, Pages 1606-1615

  Terada, Naoki ^a   Shimizu, Yosuke ^a   Kamba, Tomomi ^a   Inoue, Takahiro ^a   Maeno, Atsushi ^a   Kobayashi, Takashi ^a   Nakamura, Eijiro ^a,e   Kamoto, Toshiyuki ^a,f   Kanaji, Toshiya ^g   Maruyama, Takayuki ^g   Mikami, Yoshiki ^b   Toda, Yoshinobu ^a   Matsuoka, Toshiyuki ^c   Okuno, Yasushi ^d   Tsujimoto, Gozoh ^d   Narumiya, Shuh ^c   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF MIYAZAKI   (Japan)

^g ONO PHARMACEUTICAL CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYCLIC AMP; EP4; GENOMIC DNA; ONO AE 208; ONO AE 3208; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA EXTRACTION; DNA MICROARRAY; DRUG MECHANISM; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CASTRATION; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONE ANTAGONISTS; HUMANS; MALE; MICE; MICE, NUDE; NAPHTHALENES; PHENYLBUTYRATES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, PROSTAGLANDIN E; TREATMENT FAILURE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76749127520     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2984     Document Type: Article

References (48)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361: 859-64.
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
3. Yoshida T, Kinoshita H, Segawa T, et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 2005;65:9611-6.
4. Terada N, Shimizu Y, Yoshida T, et al. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. Prostate. Epub 2009.
5. Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, Narumiya S. Prostaglandin E2-4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 2003;9:744-9.
6. Bastien L, Sawyer N, Grygorczyk R, Metters KM, Adam M. Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. J Biol Chem 1994;269:11873-7.
7. Inoue T, Yoshida T, Shimizu Y, et al. Requirement of androgen-dependent activation of protein kinase Cζ for androgen-dependent cell proliferation in LNCaP cells and its roles in transition to androgen-independent cells. Mol Endocrinol 2006;20:3053-69.
8. Inoue T, Segawa T, Shiraishi T, et al. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005;66:332-7.
9. Shimizu Y, Segawa T, Inoue T, et al. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int 2007;100:685-90.
10. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
11. Chen Y, Hughes-Fulford M. Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer 2000;82:2000-6.
12. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible factor-1α stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 2002;277:50081-6.
13. Wang X, Klein RD. Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. Mol Carcinog 2007;46:912-23.
14. Matsuoka T, Narumiya S. The roles of prostanoids in infection and sickness behaviors. J Infect Chemother 2008;14:270-8.
15. Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006;66:9665-72.
16. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16.
17. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992;52:1598-605.
18. Klein KA, Reiter RE, Redula J, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-8.
19. Ellis WJ, Vessella RL, Buhler KR, et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996;2:1039-48.
20. Marques RB, van Weerden WM, Erkens-Schulze S, et al. The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. Eur Urol 2006;49:245-57.
21. Nagabhushan M, Miller CM, Pretlow TP, et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-6.
22. Craft N, Chhor C, Tran C, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999; 59:5030-6.
23. Inoue T, Kobayashi T, Terada N, et al. Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Expert Rev Endocrinol Metab 2007;2:689-704.
24. Wang Q, Li W, Zhang Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009;138:245-56.
25. Nelson WG, De Marzo AM, Isaacs WB. Prostate Cancer. N Engl J Med 2003;349:366-81.
26. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
27. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004;91:483-90.
28. Gregory CW, Johnson RT, Jr., Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61: 2892-8.
29. Lee DK, Chang C. Endocrine mechanisms of disease: expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab 2003;88:4043-54.
30. Kasbohm EA, Guo R, Yowell CW, et al. Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem 2005;280: 11583-9.
31. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
32. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 2004;3:1031-9.
33. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171:S36-40.
34. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69.
35. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of non-steroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004;90:93-9.
36. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64:3334-43.
37. Singer EA, Palapattu GS, van Wijngaarden E. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey. Cancer 2008;113:2053-7.
38. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006;24:2723-8.
39. Lieberman R. Chemoprevention of prostate cancer: current status and future directions. Cancer Metastasis Rev 2002;21:297-309.
40. Csiki I, Morrow JD, Sandler A, et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 2005;11:6634-40.
41. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
42. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007;282:11613-7.
43. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Δ716) knockout mice. Nat Med 2001;7:1048-51.
44. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008; 68:7750-9.
45. Iljin K, Wolf M, Edgren H, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006;66:10242-6.
46. Chell S, Kaidi A, Williams AC, Paraskeva C. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 2006;1766:104-19.
47. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002;62:28-32.
48. Chell SD, Witherden IR, Dobson RR, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 2006;66:3106-13.